| Literature DB >> 30049452 |
Mar Coll1, Luis Perea2, Ruben Boon3, Sofia B Leite4, Julia Vallverdú2, Inge Mannaerts4, Ayla Smout4, Adil El Taghdouini4, Delia Blaya2, Daniel Rodrigo-Torres2, Isabel Graupera5, Beatriz Aguilar-Bravo2, Christophe Chesne6, Mustapha Najimi7, Etienne Sokal7, Juan José Lozano8, Leo A van Grunsven9, Catherine M Verfaillie10, Pau Sancho-Bru11.
Abstract
The development of complex in vitro hepatic systems and artificial liver devices has been hampered by the lack of reliable sources for relevant cell types, such as hepatic stellate cells (HSCs). Here we report efficient differentiation of human pluripotent stem cells into HSC-like cells (iPSC-HSCs). iPSC-HSCs closely resemble primary human HSCs at the transcriptional, cellular, and functional levels and possess a gene expression profile intermediate between that of quiescent and activated HSCs. Functional analyses revealed that iPSC-HSCs accumulate retinyl esters in lipid droplets and are activated in response to mediators of wound healing, similar to their in vivo counterparts. When maintained as 3D spheroids with HepaRG hepatocytes, iPSC-HSCs exhibit a quiescent phenotype but mount a fibrogenic response and secrete pro-collagen in response to known stimuli and hepatocyte toxicity. Thus, this protocol provides a robust in vitro system for studying HSC development, modeling liver fibrosis, and drug toxicity screening.Entities:
Keywords: differentiation; disease modeling; hepatic stellate cells; in vitro liver model; liver fibrosis; liver spheroids; non-parenchymal cells; organoids; pluripotent stem cells; toxicity assessment
Mesh:
Substances:
Year: 2018 PMID: 30049452 DOI: 10.1016/j.stem.2018.05.027
Source DB: PubMed Journal: Cell Stem Cell ISSN: 1875-9777 Impact factor: 24.633